Equities research analysts at Roth Capital initiated coverage on shares of Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) in a research note issued on Thursday. The firm set a “buy” rating on the stock.

ITEK has been the subject of a number of other research reports. HC Wainwright initiated coverage on shares of Inotek Pharmaceuticals Corp. in a research report on Tuesday, September 20th. They set a “buy” rating and a $22.00 target price for the company. Piper Jaffray Cos. reissued a “buy” rating and set a $24.00 target price on shares of Inotek Pharmaceuticals Corp. in a research report on Tuesday, August 16th.

Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) traded down 0.8359% on Thursday, reaching $6.3465. The company had a trading volume of 154,206 shares. The firm has a 50-day moving average of $7.11 and a 200-day moving average of $7.84. Inotek Pharmaceuticals Corp. has a 12 month low of $5.81 and a 12 month high of $12.41. The stock’s market capitalization is $170.91 million.

COPYRIGHT VIOLATION WARNING: This piece was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and republished in violation of US & international copyright and trademark law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2016/12/01/inotek-pharmaceuticals-corp-itek-earns-buy-rating-from-analysts-at-roth-capital.html.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. GW&K Investment Management LLC increased its position in Inotek Pharmaceuticals Corp. by 13.4% in the second quarter. GW&K Investment Management LLC now owns 363,757 shares of the company’s stock valued at $2,706,000 after buying an additional 42,998 shares during the last quarter. Alps Advisors Inc. increased its position in Inotek Pharmaceuticals Corp. by 25.0% in the second quarter. Alps Advisors Inc. now owns 37,119 shares of the company’s stock valued at $276,000 after buying an additional 7,418 shares during the last quarter. Bank of New York Mellon Corp increased its position in Inotek Pharmaceuticals Corp. by 114.8% in the second quarter. Bank of New York Mellon Corp now owns 70,832 shares of the company’s stock valued at $526,000 after buying an additional 37,863 shares during the last quarter. California State Teachers Retirement System bought a new position in Inotek Pharmaceuticals Corp. during the second quarter valued at about $272,000. Finally, Janney Montgomery Scott LLC increased its position in Inotek Pharmaceuticals Corp. by 31.1% in the second quarter. Janney Montgomery Scott LLC now owns 31,015 shares of the company’s stock valued at $351,000 after buying an additional 7,350 shares during the last quarter. Institutional investors own 80.93% of the company’s stock.

About Inotek Pharmaceuticals Corp.

Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.

5 Day Chart for NASDAQ:ITEK

Receive News & Stock Ratings for Inotek Pharmaceuticals Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotek Pharmaceuticals Corp. and related stocks with our FREE daily email newsletter.